Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2005-5-17
pubmed:abstractText
1 To determine the binding characteristics of a highly potent agonist for protease-activated receptor-2 (PAR2), 2-furoyl-Leu-Ile-Gly-Arg-Leu-amide (2-furoyl-LIGRL-NH(2)), whole-cell binding assays were performed utilising a radioactive ligand, [(3)H]2-furoyl-LIGRL-NH(2). 2 Specific binding of [(3)H]2-furoyl-LIGRL-NH(2) was observed in NCTC2544 cells, dependent upon PAR2 expression, and competitively displaced by the addition of unlabeled PAR2 agonists. Scatchard analysis of specific saturation binding suggested a single binding site, with K(d) of 122+/-26.1 nM and a corresponding B(max) of 180+/-6 f mol in 3.0 x 10(5) cells. 3 The relative binding affinities of a series of modified PAR2 agonist peptides obtained from competition studies paralleled their relative EC(50) values for Ca(2+) mobilisation assays, indicating improved binding affinities by substitution with 2-furoyl at the N-terminus serine. 4 Pretreatment of cells with trypsin reduced specific binding of [(3)H]2-furoyl-LIGRL-NH(2), demonstrating direct competition between the synthetic agonist peptide and the proteolytically revealed tethered ligand for the binding site of the receptor. 5 In HCT-15 cells endogenously expressing PAR2, the binding of [(3)H]2-furoyl-LIGRL-NH(2) was displaced by addition of unlabeled ligands, Ser-Leu-Ile-Gly-Lys-Val (SLIGKV-OH) or 2-furoyl-LIGRL-NH(2). The relative binding affinity of 2-furoyl-LIGRL-NH(2) to SLIGKV-OH was comparable to its relative EC(50) value for Ca(2+) mobilisation assays. 6 The binding assay was successfully performed in monolayers of PAR2 expressing NCTC2544 and human umbilical vein endothelial cells (HUVEC), in 96- and 24-well plate formats, respectively. 7 These studies indicate that [(3)H]2-furoyl-LIGRL-NH(2) binds to human PAR2 at its ligand-binding site. The use of this radioligand will be valuable for characterising chemicals that interact to PAR2.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-10086357, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-10411588, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-10455252, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-10655102, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-10694203, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-10780990, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-10788464, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-10805786, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-10806174, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-10995771, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-11156565, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-11277570, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-11356985, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-11390426, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-11401477, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-11413129, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-11859856, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-11877338, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-12171601, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-12414536, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-12511586, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-14607272, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-14976227, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-14976230, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-4202581, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-7556175, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-7890726, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-7937743, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-8632754, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-8703006, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-8960546, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-9003384, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-9020112, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-9203642, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-9315351, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-9696685, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-9806321, http://linkedlifedata.com/resource/pubmed/commentcorrection/15765104-9862790
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
145
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
255-63
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3H]2-furoyl-LIGRL-NH2, to human PAR2.
pubmed:affiliation
Tokyo New Drug Research Laboratories, Kowa Company Limited, Higashimurayama, 27 Taylor Street, Tokyo 189-0022, Japan. t-tanke@kowa.co.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't